University of Warwick spin-out company, VirionHealth - a new biotechnology company developing novel therapeutics for respiratory viral infections, has announced that it has won non-dilutive funding worth up to $4.2 million from the US Defense Advanced Research Projects Agency (DARPA).

Founded in 2017 on pioneering research of Professors Easton and Dimmock in the School of Life Sciences, VirionHealth is developing a new class of biological antivirals to create improved therapeutics for respiratory viral infections, focusing on prevention and treatment of influenza and respiratory syncytial virus (RSV). The company is a world leader in the development of precisely engineered, non-infectious, defective interfering particles. www.virionhealth.com

Read Press Release